Novo Nordisk's pick for new chairman signals its ongoing pursuit of M&A deals
Despite what its failed bid for Ablynx may suggest, Novo Nordisk is dead serious about M&A — and it is bringing on a new chairman who helps showcase that point.
The Danish company is set to appoint veteran oil and gas exec and M&A guru Helge Lund to the role today, Reuters reports, at a time the diabetes giant is seeking to boost its blood products business during a downturn for the diabetes business. Lund replaces Goran Ando, who decided not to seek re-election after five years in the job.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.